Limbix Launches Data of The Self Help Mental Health App

Limbix, a business that develops digital therapies for teenagers, has revealed results from a study of its new SparkRx product. SparkRx is a phone-based self-guided treatment application for teenagers. The trial was published in the American Academy of Pediatrics National conference and exhibition.

 Limbix was formed in 2016 and now employs around 30 people, with ambitions to hire another 30 by the second quarter of 2022. The firm has so far secured $9 million in Series A investment, which was completed in May 2020. GSR Ventures led the round, with Sequoia Capital, Storm Ventures, NextGen Venture Partners, and BIXINK Therapeutics joining as existing investors.

The company’s first scientifically tested medication, SparkRx, is meant to assist teenagers to manage depression. The app encourages teenagers to keep track of their emotions and plan activities that will help them feel better. “They’re only supposed to use it for a few minutes a day,” explains Limbix chief medical officer, Benjamin Alouf. “[Teens] use it to arrange, prepare, and set the stage for this action before going out and doing it. Then teens report on how things went. Limbix recently presented the findings of a clinical study during the Virtual Experience of the 2021 American Academy of Pediatrics National Conference and Exhibition.

Nearly 160 teenagers between the ages of 13 and 22 were randomly selected to use SparkRx or another mental health education app in the research. Each group had mild to severe depressive symptoms, which were assessed using the PHQ-8, a standard depression questionnaire.